Increased FGF‐5 levels may promote oncogenic signalling pathways, such as the MAPK and PI3K‐Akt pathways identified in our KEGG pathway analysis, further contributing to tumour growth and resistance to immunotherapy. The gene discussed is FGF5; the disease is neoplasm.